InvestorsHub Logo
Followers 10
Posts 504
Boards Moderated 0
Alias Born 04/20/2016

Re: None

Thursday, 01/19/2017 2:06:51 PM

Thursday, January 19, 2017 2:06:51 PM

Post# of 869
Matinas receives $12.8M for warrants tendered.

Matinas announced today that 84% of all warrant holders tendered their warrants for a net to the company of $12.7M. Matinas further announced that this cash runway will take them to 2018.

By that time, Matinas will have announced results of its Phase 2a clinical study for encochleated amphotericin b, and the Phase 1 clinical study for encochleated amikacin, both of which are expected in 1H 2017, and will be well into Phases 3 and 2, respectively, for these two drugs.

If the Phase 2a and 1 clinical trials show encochleated amphotericin b, and encochleated amikacin, to be safe and effective, a partnership or buy out would appear to be likely.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MTNB News